Loading...
Loading...
Browse all stories on DeepNewz
VisitImmuneering ($IMRX) Announces Positive Phase 2a Data for Pancreatic Cancer Drug
Sep 14, 2024, 07:02 AM
Immuneering has announced positive initial Phase 2a data for its drug IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients. The data includes both complete and partial responses, indicating promising efficacy for the treatment. This development is a significant step forward in the fight against pancreatic cancer. The drug is listed under the ticker $IMRX.
View original story
Markets
Yes • 50%
No • 50%
FDA official announcements and press releases
No • 50%
Yes • 50%
Immuneering official announcements and clinical trial registries
Yes • 50%
No • 50%
Stock market data from financial platforms like NASDAQ or Bloomberg
Complete Response • 25%
Progressive Disease • 25%
Stable Disease • 25%
Partial Response • 25%
Immuneering official announcements and clinical trial registries
Above $40 • 25%
Below $20 • 25%
$20 to $30 • 25%
$30 to $40 • 25%
Stock market data from financial platforms like NASDAQ or Bloomberg
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Official announcements from Immuneering or the partnering pharmaceutical company